Pasar al contenido principal

APROXIMACIONES AL MANEJO DE LA ENFERMEDAD AVANZANDA EN CANCER DE ENDOMETRIO A TRAVES DE LA IDENTIFICACION DE BIOMARCADORES EN BIOPSIA LIQUIDA

PI17/01919

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer

  • Herrero, Cristina
  • Fuente, Adolfo de la
  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Sebastian, Víctor|||0000-0002-6873-5244
  • Prieto, Martín
  • Arruebo, Manuel
  • Abalo, Alicia
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Moreno-Bueno, Gema
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient's outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-efficient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly efficient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Diaz, Eva
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Alonso-Alconada, Lorena
  • Ferreiros, Alba
  • Abalo, Alicia
  • López Gil, Carlos
  • Oltra, Sara S.
  • de Santiago, Javier
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Sampayo, Victoria
  • Bouso, Marta
  • Arias, Efigenia
  • Cueva, Juan|||0000-0003-1389-4595
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Vilar, Ana
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
The incidence and mortality of endometrial cancer (EC) have risen in recent years, hence more precise management is needed. Therefore, we combined different types of liquid biopsies to better characterize the genetic landscape of EC in a non-invasive and dynamic manner. Uterine aspirates (UAs) from 60 patients with EC were obtained during surgery and analyzed by next-generation sequencing (NGS). Blood samples, collected at surgery, were used for cell-free DNA (cfDNA) and circulating tumor cell (CTC) analyses. Finally, personalized therapies were tested in patient-derived xenografts (PDXs) generated from the UAs. NGS analyses revealed the presence of genetic alterations in 93% of the tumors. Circulating tumor DNA (ctDNA) was present in 41.2% of cases, mainly in patients with high-risk tumors, thus indicating a clear association with a more aggressive disease. Accordingly, the results obtained during the post-surgery follow-up indicated the presence of ctDNA in three patients with progressive disease. Moreover, 38.9% of patients were positive for CTCs at surgery. Finally, the efficacy of targeted therapies based on the UA-specific mutational landscape was demonstrated in PDX models. Our study indicates the potential clinical applicability of a personalized strategy based on a combination of different liquid biopsies to characterize and monitor tumor evolution, and to identify targeted therapies.